Press release
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
6. Global Malignant Melanoma Clinical Pipeline By Company & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Registered
7. Global Malignant Melanoma Marketed Drugs Clinical Insight
7.1 Talimogene Laherparepvec (IMLYGIC)
7.2 Nivolumab (Opdivo)
7.3 Temozolomide (Temodal & Temodar)
7.4 Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegintron, Pegtron & ViraferonPeg )
7.5 Pembrolizumab (Keytruda )
7.6 Vemurafenib
7.7 Ipilimumab (Yervoy)
7.8 Cobimetinib (Cotellic)
7.9 Trametinib (Mekinist)
7.10 Tc 99m Tilmanocept (Lymphoseek)
7.11 Dabrafenib (Tafinlar)
7.12 Aldesleukin (Chiron IL-2 & Proleukin)
7.13 Interferon alpha-2b (Intron A, Viraferon & Virtron)
7.14 Interferon-beta-1b - Toray/Daiichi Sankyo (Feron)
7.15 Melanoma Vaccine - AVAX Technologies (MVax)
7.16 Interferon alpha - Swedish Orphan Biovitrim (Multiferon)
7.17 Interferon alpha-2b - Beijing Kawin Technology
7.18 Virulizin (Virulizin)
7.19 Vemurafenib Companion Diagnostic - Roche/Plexxikon (cobas 4800 BRAF V600 Mutation Test)
7.20 Dabrafenib-Trametinib Companion Diagnostic - bioMerieux/ GlaxoSmithKline/ Response Genetics (THxID-BRAF)
7.21 Interferon alpha-2b Biosimilar - Reliance Life Sciences (ReliFeron)
7.22 Technetium Tc 99m Sulfur Colloid Injection – Pharmalucence
7.23 Interferon alpha-2a (Roferon-A)
7.24 Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)
7.25 Melanoma Vaccine – GlaxoSmithKline (Melacine)
8. Competitve Landscape
8.1 AB Science
8.2 Celgene Corporation (Abraxis BioScience)
8.3 Array BioPharma
8.4 AVAX Technologies
8.5 Biogen Idec
8.6 BioVex
8.7 Bristol-Myers Squibb
8.8 Enzon Pharmaceuticals
8.9 Eisai Co
8.10 Exelixis
8.11 GlaxoSmithKline
8.12 Lorus Therapeutics (Aptose Bioscience)
8.13 Medarex
8.14 Merck
8.15 Navidea Biopharmaceuticals
8.16 Novartis
8.17 Ono Pharmaceutical
8.18 Onyx Pharmaceuticals
8.19 Pfizer
8.20 Pharmalucence (Sun Pharmaceutical)
8.21 Plexxikon
8.22 QIAGEN
8.23 Roche
8.24 Reliance Life Sciences
8.25 Servier
8.26 TC BioPharm
8.27 Viragen
Download Report: https://www.kuickresearch.com/report-Global-Malignant-Melanoma-Drug-Market-&-Clinical-Pipeline-Insight.php
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report here
News-ID: 618914 • Views: 193
More Releases from Kuick Resarch
Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research"
"Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights:
• Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
• Marketed Cancer Antibody Drug Conjugate: 9 Drugs
• Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
• Majority of Drug Trials Are For Second Line Therapy…
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027
"Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights:
• Global Cell Therapy Market: > USD 40 Billion By 2027
• Cell Therapy Clinical Trial Insight by Indication, Company and Country
• Cell Therapy Price & Product Insight By Region/Country
• Clinical…
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:
• Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026
• USA Dominates Global Small Molecule Cancer Drug Market: >50% Share
• Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs
• Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
• Small Molecule Drug Insight by Cancer
• Clinical Trials Insight…
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights:
• GCC Clinical Trial Market Opportunity: >US$ 500 Million
• GCC Disease Prevalence & Statistics
• Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials
• Clinical Trials for Cancer in GCC: > 120 Trials
• Guidelines For Conducting Clinical Trials by Country
• Ongoing Clinical Trials Insight by Country
Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration
Table of Contents
1. GCC Clinical Market Regional Insights
2. GCC Clinical Trial Market Dynamics
2.1 Driving Forces for GCC Clinical Trial…
More Releases for Melanoma
Global Melanoma Drugs Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the…
Global Drugs for Melanoma Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
Melanoma Cancer Diagnostics Market: 7 Key Takeaways
According to a latest market research by fast-growing market research and consulting firm, the global melanoma cancer diagnostics market is poised to grow at over 7% CAGR and surpass US$ 853.5 million in revenues by 2022. Fact.MR’s report forecasts that North America and Europe will remain the most lucrative markets for melanoma cancer diagnostics market globally. Key takeaways from Fact.MR’s report are,
Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=57
• The U.S. melanoma cancer…
Melanoma Treatment Market – Global Industry Insights, 2025
Melanoma is a type of skin cancer that develops from the pigment cells known as melanocytes. It is caused due to high exposure to ultraviolet rays, which leads to sunburn, especially at high altitudes. Melanoma is categorized into three: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in…
Melanoma Treatment Market – Global Industry Insights, 2025
Melanoma is a type of skin cancer that develops from the pigment cells known as melanocytes. It is caused due to high exposure to ultraviolet rays, which leads to sunburn, especially at high altitudes. Melanoma is categorized into three: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in…
